What Is the Success Rate of a Bone Marrow Transplant?

Bone marrow transplant success rates range from roughly 50% to over 90%, depending on the disease being treated, the patient’s age and overall health, the type of transplant, and how well the donor matches. There is no single number that captures the “success rate” of this procedure because a transplant for aplastic anemia in a young patient looks nothing like a transplant for advanced leukemia in someone over 50. Understanding what drives that wide range matters far more than chasing a single statistic.

Why the Disease Being Treated Matters Most

The underlying disease is the single biggest factor determining whether a transplant succeeds. For severe aplastic anemia, where the bone marrow has essentially stopped producing blood cells, transplant from a matched sibling donor produces roughly 86% survival at 10 years in patients aged one to twenty. Even with unrelated donors, children can achieve around 90% survival when transplanted as a first-line treatment. That number drops significantly with age: patients between 21 and 40 see about 76% survival, while those over 40 fall to around 55%.¹

Sickle cell disease presents a different picture. An early landmark study of young patients with symptomatic sickle cell disease reported four-year survival of 91% and event-free survival of 73% after transplant from matched sibling donors.² Transplant is potentially curative for sickle cell disease, though achieving stable engraftment with less-intensive conditioning regimens has proven more difficult in pediatric patients with hemoglobinopathies than in adults with blood cancers.³

Blood cancers generally carry tougher odds. A meta-analysis of patients with relapsed or treatment-resistant peripheral T-cell lymphoma found that both allogeneic and autologous transplant recipients had roughly 50–55% overall survival at three years.⁴ For adult T-cell leukemia, outcomes are even harder: patients transplanted while not in complete remission had a three-year overall survival of just under 17%, compared with about 44% for those who were in remission at the time of transplant.⁵ The gap between those two numbers illustrates how much disease status at the time of transplant influences the outcome.

For multiple myeloma treated with autologous transplant, one study found one-year overall survival of about 93% and three-year overall survival around 77%.⁶ Among long-term survivors followed for a median of 13 years after diagnosis, the 15-year overall survival rate was about 62%, though only about 19% remained progression-free that long, meaning most patients eventually relapsed but many lived years after relapse with additional treatments.⁷

Autologous vs. Allogeneic Transplants

These two types of transplant carry fundamentally different risk profiles. In an autologous transplant, you receive your own stem cells back after high-dose chemotherapy. The procedure has lower complication rates since your body is not dealing with foreign cells, but it also lacks the immune attack on residual cancer that a donor’s cells can provide. In an allogeneic transplant, stem cells come from another person. This introduces the possibility of a graft-versus-leukemia effect, where the donor’s immune cells recognize and destroy lingering cancer cells, but it also introduces the risk of graft-versus-host disease, where those same donor cells attack your healthy tissues.

The trade-off shows up clearly in the numbers. In a study of patients with primary plasma cell leukemia, those who received allogeneic transplants had a lower relapse rate at 36 months (about 46% vs. 68%) but much higher non-relapse mortality (about 27% vs. 7%).⁸ A similar pattern appeared in the T-cell lymphoma meta-analysis: allogeneic transplant had treatment-related mortality of about 32% at three years compared with just 7% for autologous, yet overall survival rates were comparable because the allogeneic group relapsed less often.⁴ The lower relapse rate and the higher procedure-related death rate roughly cancel each other out for some diseases, which is why the choice between autologous and allogeneic depends heavily on the specific cancer and the patient’s ability to tolerate the risks.

How Donor Matching Affects the Odds

For allogeneic transplants, the degree of immune compatibility between donor and recipient has historically been considered critical. A fully matched sibling donor has long been considered the gold standard. But advances in transplant protocols have narrowed the gap between donor types considerably. A study comparing matched unrelated donor transplants with haploidentical (half-matched, typically a parent or child) transplants found remarkably similar outcomes: one-year overall survival was 73% for matched unrelated donors and 74% for haploidentical donors, with no significant difference in disease-free survival, relapse, or treatment-related mortality.⁹ The practical implication is significant: nearly everyone has a haploidentical donor available, so the old barrier of finding a perfect match is less of a roadblock than it once was.

Stem cell source also matters, though perhaps less than expected. A matched comparison of bone marrow, peripheral blood stem cells, and cord blood transplants found five-year overall survival of about 66%, 51%, and 53%, respectively. The differences were not statistically significant, though complication patterns varied. Cord blood recipients had higher death rates from complications, while peripheral blood stem cell recipients were more likely to die from relapse. Peripheral blood engrafted the fastest, with a median of 14 days to neutrophil recovery compared with 19 and 20 days for bone marrow and cord blood.¹⁰

Age, Fitness, and Disease Stage at Transplant

Older age has long been considered a risk factor for poorer transplant outcomes. Early data suggested dismal survival in patients over 50, though many of those patients were also transplanted with advanced disease.¹¹ More recent evidence with reduced-intensity conditioning paints a more nuanced picture. A study of older adults with AML or myelodysplastic syndrome who received reduced-intensity transplants found no significant impact of age on treatment-related death, relapse, disease-free survival, or overall survival when comparing different age groups.¹² In other words, what matters more is how healthy you are going into the transplant, not simply your birth year.

Disease stage at the time of transplant is arguably more predictive than age. Patients transplanted in first remission or at an early stage consistently fare better than those transplanted during relapse or with active, uncontrolled disease. For AML, white blood cell count and whether the patient subsequently relapses are among the strongest independent predictors of survival.¹³

The Conditioning Regimen Trade-Off

Before transplant, patients receive a conditioning regimen of chemotherapy, sometimes with radiation, to destroy existing marrow and make room for the new cells. The intensity of that regimen creates another trade-off. A randomized trial comparing full-intensity (myeloablative) conditioning with reduced-intensity conditioning in AML and myelodysplastic syndrome patients found that the reduced-intensity approach had lower treatment-related mortality (about 4% vs. 16%) but significantly higher relapse rates (about 48% vs. 14%). Relapse-free survival favored the full-intensity approach at roughly 68% compared with 47%.¹⁴ The trial actually stopped enrolling early because the relapse difference was so stark. This is why conditioning intensity is tailored to each patient’s ability to tolerate the treatment: full-intensity works better against the disease, but not everyone can survive the regimen itself.

Graft-versus-Host Disease as a Double-Edged Sword

Graft-versus-host disease is the most common serious complication unique to allogeneic transplants, and understanding it is essential for interpreting success rates. The donor’s immune cells can attack the recipient’s skin, gut, liver, and other organs, causing anything from a mild rash to life-threatening organ failure. But GVHD also signals an immune response that can target residual cancer cells. Chronic GVHD, in particular, has been linked to lower relapse rates after both full-intensity and reduced-intensity conditioning.¹⁵

The tension is real: GVHD can simultaneously improve survival by reducing relapse risk and increase mortality by causing organ damage and making the patient vulnerable to infections.¹⁶ This is why transplant teams spend enormous effort trying to calibrate immunosuppression: enough to prevent severe GVHD, not so much that the beneficial graft-versus-leukemia effect disappears.

Graft Failure, Infection, and Relapse

Beyond GVHD, three other complications heavily influence outcomes. Graft failure, where the transplanted cells fail to establish themselves in the bone marrow, is more common with HLA-mismatched or unrelated donors, in patients who have received many prior blood transfusions, and with reduced-intensity conditioning.¹⁷ When graft failure occurs, a second transplant is typically the only option for long-term survival. Salvage transplants from haploidentical donors have shown one-year overall survival of about 56%.¹⁸

Infection is the leading cause of early death after transplant. Among patients with acute leukemia who died within 50 days of allogeneic transplant, infection accounted for about two-thirds of deaths, with pneumonia and sepsis being the most common culprits. Organ failure accounted for another 17%.¹⁹

Disease relapse remains the most common reason transplants ultimately fail to cure the underlying condition. The prognosis after relapse depends on how soon it happens (relapse within six months of transplant carries the worst outlook), the specific disease, how much cancer has returned, and whether there is room to intensify the immune attack from the graft or try a second transplant.²⁰ Encouragingly, outcomes after second transplants for relapsed AML have been improving over time: two-year overall survival after a second transplant rose from about 23% for procedures done in 2000–2004 to 35% for those done in 2015–2019.²¹

Long-Term Survival and Late Effects

Surviving the first two years is a strong predictor of long-term success. A large study found that patients who were disease-free at two years after allogeneic transplant had an 89% probability of surviving at least five more years. For aplastic anemia patients, mortality risk by the sixth year was no different from the general population. For leukemia patients, however, elevated mortality persisted for years, up to nine years for AML and even longer for certain types.²²

Even among five-year survivors, the picture is not entirely reassuring. A study following transplant survivors for up to 30 years found that death rates remained four to nine times higher than expected for the general population, translating to an estimated 30% shorter life expectancy regardless of current age. The leading causes of excess death were second cancers and recurrence of the original disease, followed by infections, chronic GVHD, respiratory diseases, and cardiovascular disease.²³ For autologous transplant recipients specifically, life expectancy was reduced by about seven years on average, though this gap has been shrinking in more recent eras, from about five years of life lost for transplants done in 1981–1999 down to less than two years lost for those done in 2011–2014.²⁴

How CAR-T Therapy Fits Into the Picture

Chimeric antigen receptor T-cell (CAR-T) therapy has changed the treatment landscape for certain blood cancers, and its relationship with transplant is evolving. For patients with B-cell acute lymphoblastic leukemia who achieve remission through CAR-T therapy and then proceed to allogeneic transplant, outcomes at four years are comparable to those who achieved remission through chemotherapy before transplant: leukemia-free survival of about 70% in the CAR-T group versus 64% in the chemotherapy group, with similar relapse and treatment-related death rates.²⁵ The CAR-T group in that study actually had more patients with high-risk disease features, yet outcomes were equivalent. This suggests CAR-T therapy can serve as an effective bridge to transplant for patients who would not have achieved remission with chemotherapy alone.

Racial and Socioeconomic Disparities

Success rates do not distribute equally across populations. In the United States, Black patients face disparities at every stage of the transplant process: access to donors, access to the procedure itself, and outcomes after transplant. These disparities are more pronounced for allogeneic transplants, where finding a matched donor from the same ethnic background is harder due to the greater genetic diversity in donor registries.²⁶ A systematic review found that eight of eleven studies identified substantial variation in access to transplant for ethnic minorities, and the majority of studies evaluating African American patients specifically showed significantly elevated mortality compared with white patients.²⁷ Race in the U.S. context often serves as a proxy for differences in insurance coverage, socioeconomic status, and distance to transplant centers, all of which compound the biological challenge of finding well-matched donors.

Quality of Life After Transplant

Surviving a transplant and returning to a normal life are not the same thing. Research on long-term survivors generally shows that most report good to excellent quality of life, and in some areas they adjust even better than patients who stayed on maintenance chemotherapy.²⁸ Quality of life tends to improve over time, with meaningful recovery documented in both physical and mental well-being in the years following transplant.²⁹

That said, a meaningful minority struggle. About 20% of transplant survivors in one study had not returned to full-time work nearly three and a half years after the procedure. Sexual dysfunction, altered body image, and fatigue were commonly reported problems. Depression and anxiety symptoms were significant, and the presence of depressive symptoms was one of the strongest predictors of poorer quality of life.²⁸

The Psychological Toll on Patients and Caregivers

The transplant process involves prolonged isolation, extreme vulnerability to infection, and uncertainty about the outcome. About one in five patients report clinically significant post-traumatic stress symptoms six months after transplant, with hypervigilance and avoidance being the most common.³⁰ The psychological burden extends beyond the patient. Caregivers actually report PTSD at higher rates than the patients themselves, and those with PTSD experience significantly more distress related to uncertainty, financial strain, and health burden.³¹ Caregivers often show high levels of anxiety and depression even before the transplant takes place.³²

What Transplant Looks Like for Children

Pediatric patients generally tolerate transplant better than adults and have higher survival rates for most diseases. But the developing brain introduces a unique vulnerability. Children under three who received total-body irradiation as part of their conditioning showed significantly lower IQ scores five years later compared with those who received chemotherapy-only conditioning. The youngest patients experienced cognitive declines during the first year after transplant. Those who did not receive radiation largely recovered in subsequent years, while those who did receive radiation stabilized at a lower level of functioning without catching back up.³³

Beyond cognition, a study of pediatric transplant survivors in China found that roughly a third to half of young children did not meet developmental standards across various domains including cognitive, motor, and language development. Among older children and adolescents, about 16% met criteria for depression, 10% for anxiety, and over 40% reported obsessive-compulsive symptoms.³⁴ These findings highlight that for children, “success” measured purely as survival misses a significant part of the story. Long-term developmental follow-up and psychological support are a necessary part of pediatric transplant care, and families weighing the decision should know that survival is only one dimension of the outcome they are signing up for.